Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
10 "Young Ho Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Corrigenda and Errata
Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, Young Ho Kim, Dong Soo Han, Hirotoshi Yuasa, Junichi Tabira, Naoki Isogawa, Shoko Arai, Isao Kawaguchi, Toshifumi Hibi
Intest Res 2018;16(3):499-501.   Published online July 27, 2018
DOI: https://doi.org/10.5217/ir.2018.16.3.499
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Post-inflammatory Abdominal Pain in Patients with Inflammatory Bowel Disease During Remission: A Comprehensive Review
    Kazuya Takahashi, Iman Geelani Khwaja, Jocelyn Rachel Schreyer, David Bulmer, Madusha Peiris, Shuji Terai, Qasim Aziz
    Crohn's & Colitis 360.2021;[Epub]     CrossRef
  • Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata
    Oki Kikuchi, Daisuke Saito, Miki Miura, Haruka Wada, Ryo Ozaki, Sotaro Tokunaga, Shintaro Minowa, Masahiro Fukuyama, Tatsuya Mitsui, Akihito Sakuraba, Mari Hayashida, Jun Miyoshi, Minoru Matsuura, Manabu Ohyama, Tadakazu Hisamatsu
    Clinical Journal of Gastroenterology.2020; 13(5): 788.     CrossRef
  • Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
    Gerasimos Evangelatos, Vasiliki Koulouri, Alexios Iliopoulos, George E Fragoulis
    Therapeutic Advances in Musculoskeletal Disease.2020;[Epub]     CrossRef
  • RETRACTED: Crystal structure, anti-cervical cancer activity and docking studies of a new heterocycles compound
    Peng Li, Xin Ge, Hong-Li Wu
    Main Group Chemistry.2019; 18(2): 63.     CrossRef
  • 5,470 View
  • 69 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Original Articles
IBD
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, Young Ho Kim, Dong Soo Han, Hirotoshi Yuasa, Junichi Tabira, Naoki Isogawa, Shoko Arai, Isao Kawaguchi, Toshifumi Hibi
Intest Res 2018;16(2):233-245.   Published online April 30, 2018
DOI: https://doi.org/10.5217/ir.2018.16.2.233
AbstractAbstract PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/>

Tofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily (BID) for 8 weeks. Clinical responders in OCTAVE Induction were re-randomized to 52 weeks' therapy with placebo, tofacitinib 5 mg BID, or tofacitinib 10 mg BID.

Methods

We conducted post-hoc efficacy and safety analyses of East Asian patients in OCTAVE Induction 1 and 2 and OCTAVE Sustain.

Results

A total of 121 East Asian (Japan, Korea, and Taiwan) patients were randomized in OCTAVE Induction 1 and 2 (placebo, n=26; tofacitinib 10 mg BID, n=95), and 63 in OCTAVE Sustain (placebo, n=20; tofacitinib 5 mg BID, n=22; tofacitinib 10 mg BID, n=21). At week 8 of OCTAVE Induction 1 and 2, 18.9% of patients (18/95) achieved remission with tofacitinib 10 mg BID versus 3.8% (1/26) with placebo. In OCTAVE Sustain, the week 52 remission rates were 45.5% (10/22), 47.6% (10/21), and 15.0% (3/20) with 5 mg BID, 10 mg BID, and placebo, respectively. Adverse event rates were similar between groups in OCTAVE Induction and numerically higher with tofacitinib in OCTAVE Sustain. Serious adverse event rates were similar across groups in all studies. Infections were numerically more frequent with tofacitinib than placebo. Increases in serum lipid levels were observed with tofacitinib.

Conclusions

In East Asian patients with UC, tofacitinib demonstrated numerically greater efficacy versus placebo as induction and maintenance therapy, with a safety profile consistent with the global study population. ClinicalTrials.gov: NCT01465763; NCT01458951; NCT01458574.

Citations

Citations to this article as recorded by  
  • Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
    Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis
    Jian Zeng, Zhong Wang, Xiao-Jun Yang
    European Journal of Clinical Pharmacology.2022; 78(7): 1069.     CrossRef
  • Personalized medicine in inflammatory bowel disease: Perspectives on Asia
    Su Hyun Park, Sang Hyoung Park
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
  • Safety and efficacy of long‐term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open
    Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Hyo Jong Kim, Byong Duk Ye, Shoko Arai, Masato Hoshi, Hirotoshi Yuasa, Junichi Tabira, Shigeyuki Toyoizumi, Nanzhi Shi, Joon‐suk Woo, Toshifumi Hibi
    Journal of Gastroenterology and Hepatology.2022; 37(10): 1884.     CrossRef
  • Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
    Soo-Young Na, You Sun Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 906.     CrossRef
  • Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis
    Brittany N. Palasik, Hongmei Wang
    Journal of Pharmacy Practice.2021; 34(6): 913.     CrossRef
  • Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
    Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
    Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275.     CrossRef
  • Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
    Toshifumi Hibi, Isao Kamae, Philippe Pinton, Lyann Ursos, Ryuichi Iwakiri, Greg Hather, Haridarshan Patel
    Intestinal Research.2021; 19(1): 53.     CrossRef
  • Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
    Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
    Intestinal Research.2021; 19(4): 386.     CrossRef
  • Post-inflammatory Abdominal Pain in Patients with Inflammatory Bowel Disease During Remission: A Comprehensive Review
    Kazuya Takahashi, Iman Geelani Khwaja, Jocelyn Rachel Schreyer, David Bulmer, Madusha Peiris, Shuji Terai, Qasim Aziz
    Crohn's & Colitis 360.2021;[Epub]     CrossRef
  • Multiple esophageal ulcers due to tofacitinib 10 mg twice daily for ulcerative colitis
    Keiichi Tominaga, Mimari Kanazawa, Kazuhiro Takenaka, Takanao Tanaka, Takeshi Sugaya, Koh Fukushi, Yuka Takagi, Kazunori Nagashima, Keiichiro Abe, Naoya Izawa, Kohei Tsuchida, Makoto Iijima, Kenichi Goda, Hidetsugu Yamagishi, Atsushi Irisawa
    Clinical Journal of Gastroenterology.2020; 13(3): 340.     CrossRef
  • Interleukin 23 and autoimmune diseases: current and possible future therapies
    Ahmad Ismail Khaled Abdo, Gee Jun Tye
    Inflammation Research.2020; 69(5): 463.     CrossRef
  • A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis
    Keiichi Tominaga, Mimari Kanazawa, Takanao Tanaka, Shunsuke Kojimahara, Takeshi Sugaya, Shoko Watanabe, Akira Yamamiya, Yuichi Majima, Makoto Iijima, Kenichi Goda, Atsushi Irisawa
    Medicina.2020; 56(11): 595.     CrossRef
  • Inhibidores de la vía de señalización JAK-STAT en el tratamiento de las enfermedades inmunomediadas
    José M. Serra López-Matencio, Alberto Morell Baladrón, Santos Castañeda
    Medicina Clínica.2019; 152(9): 353.     CrossRef
  • Interleukin-13: A promising therapeutic target for autoimmune disease
    Yan-Mei Mao, Chan-Na Zhao, Jing Leng, Rui-Xue Leng, Dong-Qing Ye, Song Guo Zheng, Hai-Feng Pan
    Cytokine & Growth Factor Reviews.2019; 45: 9.     CrossRef
  • JAK-STAT inhibitors for the treatment of immunomediated diseases
    José M. Serra López-Matencio, Alberto Morell Baladrón, Santos Castañeda
    Medicina Clínica (English Edition).2019; 152(9): 353.     CrossRef
  • Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
    Ferdinando D’Amico, Tommaso Lorenzo Parigi, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
    Therapeutic Advances in Gastroenterology.2019;[Epub]     CrossRef
  • Inhibitors of the Janus Kinases
    Elisabetta Antonelli, Gabriele Torti, Gabrio Bassotti
    Journal of Clinical Gastroenterology.2019; 53(9): 635.     CrossRef
  • Novel oral-targeted therapies for mucosal healing in ulcerative colitis
    Elisabetta Antonelli, Vincenzo Villanacci, Gabrio Bassotti
    World Journal of Gastroenterology.2018; 24(47): 5322.     CrossRef
  • 8,657 View
  • 205 Download
  • 22 Web of Science
  • 19 Crossref
Close layer
Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
Nam Hee Kim, Yoon Suk Jung, Chang Mo Moon, Shin Yeong Lee, Eun Ran Kim, Young Ho Kim, Chang Kyun Lee, Suck Ho Lee, Jae Hak Kim, Kyu Chan Huh, Soon Man Yoon, Hyun Joo Song, Sun-Jin Boo, Hyun Joo Jang, You Sun Kim, Kang-Moon Lee, Jeong Eun Shin, Dong Il Park
Intest Res 2014;12(4):281-286.   Published online October 27, 2014
DOI: https://doi.org/10.5217/ir.2014.12.4.281
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Several recent studies have reported that the early use of infliximab (IFX) improves the prognosis of Crohn's disease (CD). However, no data are available from Asian populations, as the forementioned studies have all been conducted in Western countries. The aim of the current study was to evaluate the impact of early use of IFX on the prognosis of Korean patients with CD.

Methods

Patients with a diagnosis of CD established between July 1987 and January 2012 were investigated in 12 university hospitals in Korea. Because insurance coverage for IFX treatment began in August 2005, patients were assigned to either of 2 groups based on diagnosis date. The first group included patients diagnosed from July 1987 to December 2005, and the second from January 2006 to January 2012. We compared the cumulative probabilities of operation and reoperation between the two groups using the Kaplan-Meier method and a log-rank test.

Results

Of the 721 patients investigated, 443 (61.4%) comprized the second group. Although the cumulative probabilities of immunosuppressant (P<0.001) and IFX use (P<0.001) after diagnosis were significantly higher in the second group, there were no significant differences in cumulative probabilities of operation (P=0.905) or reoperation (P=0.418) between two groups.

Conclusions

The early use of IFX did not reduce CD-related surgery requirements in Korean patients with CD. These study results suggest that the early use of IFX may have little impact on the clinical outcome of CD in Korean patients in the setting of a conventional step-up algorithm.

Citations

Citations to this article as recorded by  
  • The Potential of Molecular Remission: Tissue Neutrophil Elastase Is Better Than Histological Activity for Predicting Long-Term Relapse in Patients With Ulcerative Colitis in Endoscopic Remission
    Yu Kyung Jun, Hyeon Jeong Oh, Ji Ae Lee, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
    Inflammatory Bowel Diseases.2025; 31(2): 514.     CrossRef
  • Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
    Yu Kyung Jun, Eunjeong Ji, Hye Ran Yang, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis
    Dan Dou, Fangyi Zhang, Xin Deng, Yun Ma, Shuqing Wang, Xingyu Ji, Xihan Zhu, Dianpeng Wang, Shengsheng Zhang, Luqing Zhao
    Heliyon.2023; 9(9): e19609.     CrossRef
  • Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
    Rasmus Goll, Øystein K. Moe, Kay-Martin Johnsen, Renate Meyer, Joachim Friestad, Mona D. Gundersen, Hege Kileng, Knut Johnsen, Jon R. Florholmen
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Editorial: does anti‐TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question
    Ashish Srinivasan, Daniel R. van Langenberg
    Alimentary Pharmacology & Therapeutics.2021; 54(5): 718.     CrossRef
  • Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases
    Cong-Qiu Chu
    Chinese Medical Journal.2021; 134(21): 2525.     CrossRef
  • A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD
    Kenechukwu O Chudy-Onwugaje, Kaci E Christian, Francis A Farraye, Raymond K Cross
    Inflammatory Bowel Diseases.2019; 25(5): 820.     CrossRef
  • Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
    Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
    Middle East Journal of Digestive Diseases.2019; 12(1): 12.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
    Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
    Gut and Liver.2018; 12(5): 544.     CrossRef
  • Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
    Jae Myung Cha, Dong Il Park, Sang Hyoung Park, Jeong Eun Shin, Wan Soo Kim, Suk-Kyun Yang
    Journal of Korean Medical Science.2017; 32(1): 85.     CrossRef
  • Fecal microbiota transplantation for refractory Crohn's disease
    Seon Ho Bak, Hyun Ho Choi, Jinhee Lee, Mi Hee Kim, Youn Hee Lee, Jin Su Kim, Young-Seok Cho
    Intestinal Research.2017; 15(2): 244.     CrossRef
  • Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study
    Sang Hyoung Park, Sung Wook Hwang, Min Seob Kwak, Wan Soo Kim, Jeong-Mi Lee, Ho-Su Lee, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
    Digestive Diseases and Sciences.2016; 61(7): 2060.     CrossRef
  • Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
    Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Chang Kyun Lee, Hyo Jong Kim, Kang-Moon Lee, You Sun Kim, Chang Soo Eun, Sung-Ae Jung, Suk-Kyun Yang, Jun Lee, Tae-Oh Kim, Yunho Jung, Geom Seog Seo, Soon Man Yoon
    Gut and Liver.2016;[Epub]     CrossRef
  • The Efficiency of Intravenous Iron Therapy in Korean Inflammatory Bowel Disease Patients
    Kyeong Ok Kim
    Gut and Liver.2016; 10(4): 487.     CrossRef
  • Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam
    Eun Ji Lee, Tae Oh Kim, Geun Am Song, Jong hun Lee, Hyung Wook Kim, Sam Ryong Jee, Seun Ja Park, Hyun Jin Kim, Jong Ha Park
    Intestinal Research.2016; 14(1): 30.     CrossRef
  • Advanced age impacts surgical characteristics and postoperative course in patients with Crohn's disease
    Stanislaus Argeny, Anton Stift, Martina Mittlböck, Amy C. Lord, Svenja Maschke, Mathias Schneeweiß, Stefan Riss
    International Journal of Surgery.2016; 33: 182.     CrossRef
  • The clinical usefulness of a web-based messaging system between patients with Crohn disease and their physicians
    Da Eun Jeong, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Jin Tae Jung, Seong Woo Jeon, Hyun Seok Lee, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho
    Medicine.2016; 95(26): e4028.     CrossRef
  • The clinical characteristics of patients with free perforation in Korean Crohn’s disease: results from the CONNECT study
    Young Seok Doh, You Sun Kim, Song I Bae, Jong Pil Im, Jae Hee Cheon, Byong Duk Ye, Ji Won Kim, Young Sook Park, Ji Hyun Lee, Young-Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
    BMC Gastroenterology.2015;[Epub]     CrossRef
  • Management of Anemia in Patients with Inflammatory Bowel Disease
    Kyeong Ok Kim
    The Korean Journal of Gastroenterology.2015; 65(3): 145.     CrossRef
  • Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
    Byong Duk Ye
    Intestinal Research.2014; 12(4): 263.     CrossRef
  • 5,798 View
  • 60 Download
  • 20 Web of Science
  • 21 Crossref
Close layer
Commentary
Crohn's Disease Clinical Network and Cohort (CONNECT) Study: The First Step Toward Nationwide Multicenter Research of Crohn's Disease in Korea
Jae Hee Cheon, You Sun Kim, Byong Duk Ye, Kang Moon Lee, Young Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
Intest Res 2014;12(3):173-175.   Published online July 25, 2014
DOI: https://doi.org/10.5217/ir.2014.12.3.173
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Modern treatment of perianal fistulas following Crohn’s disease
    A.L. Bejanyan, A.A. Bumbazhai, K.N. Petrenko, A.A. Sumbaev, A.V. Matinyan, I.I. Eremin
    Regenerative biotechnologies, preventive, digital and predictive medicine.2024; 1(2): 49.     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • Clinical Characteristics of Korean Patients with Elderly-Onset Crohn’s Disease: Results from the Prospective CONNECT Study
    You Sun Kim, Min Jeong Na, Byong Duk Ye, Jae Hee Cheon, Jong Pil Im, Joo Sung Kim
    Gut and Liver.2022; 16(6): 995.     CrossRef
  • Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
    Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
    Gut and Liver.2022; 16(6): 907.     CrossRef
  • Treatment Strategy for Perianal Fistulas in Crohn Disease Patients: The Surgeon’s Point of View
    Jong Lyul Lee, Yong Sik Yoon, Chang Sik Yu
    Annals of Coloproctology.2021; 37(1): 5.     CrossRef
  • Epidemiology and diagnosis of inflammatory bowel diseases
    Kang-Moon Lee
    Journal of the Korean Medical Association.2021; 64(9): 579.     CrossRef
  • Clinical Features of Intra-Abdominal Abscess and Intestinal Free-Wall Perforation in Korean Patients with Crohn’s Disease: Results from the CONNECT Study
    Seok-Hoo Jeong, Ja Sung Choi, Jin Woo Kim, Hee Man Kim, Hyun-Soo Kim, Jong Pil Im, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Won Ho Kim, Byong Duk Ye, Young-Ho Kim, Dong Soo Han
    Journal of Clinical Medicine.2020; 10(1): 116.     CrossRef
  • Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East
    Masoud M Malekzadeh, Alireza Sima, Sudabeh Alatab, Anahita Sadeghi, Nasser Ebrahimi Daryani, Payman Adibi, Iradj Maleki, Hassan Vossoughinia, Hafez Fakheri, Abbas Yazdanbod, Seyed Alireza Taghavi, Rahim Aghazadeh, Mohammad Hassan Somi, Kazem Zendedel, Hom
    Intestinal Research.2019; 17(3): 330.     CrossRef
  • Postoperative course of Crohn disease according to timing of bowel resection
    Ji Min Lee, Kang-Moon Lee, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, Dong Soo Han, Chang Kyun Lee, Hyun-Ju Park
    Medicine.2018; 97(16): e0459.     CrossRef
  • Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
    Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
    Gut and Liver.2018; 12(5): 544.     CrossRef
  • Second Korean Guidelines for the Management of Crohn's Disease
    Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
    The Korean Journal of Gastroenterology.2017; 69(1): 29.     CrossRef
  • Second Korean guidelines for the management of Crohn's disease
    Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
    Intestinal Research.2017; 15(1): 38.     CrossRef
  • Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
    Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
    The American Journal of the Medical Sciences.2017; 353(5): 439.     CrossRef
  • A coding variant inFTOconfers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD
    Han Sang Kim, Jae Hee Cheon, Eun Suk Jung, Joonhee Park, Sowon Aum, Soo Jung Park, Sungho Eun, Jinu Lee, Ulrich Rüther, Giles S H Yeo, Marcella Ma, Kyong Soo Park, Takeo Naito, Yoichi Kakuta, Ji Hyun Lee, Won Ho Kim, Min Goo Lee
    Gut.2017; 66(11): 1926.     CrossRef
  • Development of a Novel Predictive Model for the Clinical Course of Crohnʼs Disease
    Yehyun Park, Jae Hee Cheon, Yi Lang Park, Byong Duk Ye, You Sun Kim, Dong Soo Han, Joo Sung Kim, Sung Noh Hong, Young Ho Kim, Seong Ran Jeon, Won Ho Kim
    Inflammatory Bowel Diseases.2017; 23(7): 1071.     CrossRef
  • Influence of age at diagnosis on the clinical characteristics of Crohn's disease in Korea: Results from the CONNECT study
    Sung Wook Hwang, Jee Hyun Kim, Jong Pil Im, Byong Duk Ye, Hoon Sup Koo, Kyu Chan Huh, Jae Hee Cheon, You Sun Kim, Young Ho Kim, Dong Soo Han, Won Ho Kim, Joo Sung Kim
    Journal of Gastroenterology and Hepatology.2017; 32(10): 1716.     CrossRef
  • Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study
    Bun Kim, Jae Hee Cheon, Hyun Jin Moon, Yi Rang Park, Byong Duk Ye, Suk‐Kyun Yang, Geom Seog Seo, Byung Ik Jang, You Sun Kim, Joo Sung Kim, Dong Soo Han, Young‐Ho Kim, Won Ho Kim
    Journal of Gastroenterology and Hepatology.2016; 31(1): 126.     CrossRef
  • Deep resequencing of 131 Crohn's disease associated genes in pooled DNA confirmed three reported variants and identified eight novel variants
    Sung Noh Hong, Changho Park, Soo Jung Park, Chang Kyun Lee, Byong Duk Ye, You Sun Kim, Seungbok Lee, Jeesoo Chae, Jong-Il Kim, Young-Ho Kim
    Gut.2016; 65(5): 788.     CrossRef
  • Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn’s Disease: Results from the CONNECT Study
    Jee Hye Kwon, Jong Pil Im, Byong Duk Ye, Jae Hee Cheon, Hyun Joo Jang, Kang Moon Lee, You Sun Kim, Sang Wook Kim, Young Ho Kim, Geun Am Song, Dong Soo Han, Won Ho Kim, Joo Sung Kim
    Gut and Liver.2016; 10(4): 595.     CrossRef
  • The clinical characteristics of patients with free perforation in Korean Crohn’s disease: results from the CONNECT study
    Young Seok Doh, You Sun Kim, Song I Bae, Jong Pil Im, Jae Hee Cheon, Byong Duk Ye, Ji Won Kim, Young Sook Park, Ji Hyun Lee, Young-Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
    BMC Gastroenterology.2015;[Epub]     CrossRef
  • Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn’s Disease Patients: Results from the CONNECT Study
    Chang Mo Moon, Sung-Ae Jung, Seong-Eun Kim, Hyun Joo Song, Yunho Jung, Byong Duk Ye, Jae Hee Cheon, You Sun Kim, Young-Ho Kim, Joo Sung Kim, Dong Soo Han, Mathias Chamaillard
    PLOS ONE.2015; 10(12): e0144390.     CrossRef
  • Long-term Clinical Outcomes of Urban Versus Rural Environment in Korean Patients with Crohn's Disease: Results from the CONNECT Study
    Y. S. Jung, D. I. Park, B. D. Ye, J. H. Cheon, Y. S. Kim, Y. H. Kim, J. S. Kim, H. S. Chae, G. H. Baik, D. S. Han
    Journal of Crohn's and Colitis.2015; 9(3): 246.     CrossRef
  • Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future
    Jung Won Lee, Jong Pil Im, Jae Hee Cheon, You Sun Kim, Joo Sung Kim, Dong Soo Han
    Intestinal Research.2015; 13(3): 213.     CrossRef
  • Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study
    Sinyoung Park, Yang Hee Noh, Sun Young Rha, Won Ho Kim, Jae Hee Cheon
    Intestinal Research.2015; 13(3): 274.     CrossRef
  • Crohn's disease in Korea: past, present, and future
    Kang-Moon Lee, Ji Min Lee
    The Korean Journal of Internal Medicine.2014; 29(5): 558.     CrossRef
  • 7,055 View
  • 80 Download
  • 23 Web of Science
  • 25 Crossref
Close layer
Original Article
Usefulness of Polyp Detection Rate as a Quality Indicator in Colonoscopy
Su Hee Lee, Dong Il Park, Jun Mo Sung, Jae Hyun Jang, Seung Ho Ryu, Young Ho Kim, Suck-Ho Lee, Chang Kyun Lee, Chang Soo Eun, Dong Soo Han
Intest Res 2011;9(2):105-111.   Published online August 30, 2011
DOI: https://doi.org/10.5217/ir.2011.9.2.105
AbstractAbstract PDF
Background/Aims
The adenoma detection rate (ADR) has been proposed as a quality indicator of colonoscopy; however, ADR cannot be measured easily with commonly used endoscopy reporting systems because substantial time and effort is required to acquire data from histologic assessments. The purpose of this study was to determine if polyp detection rate (PDR) could be used as a valid proxy for ADR. Methods: A total of 1,156 consecutive, asymptomatic, individuals of average risk between 50 and 75 years-of-age who underwent screening colonoscopies at four tertiary medical centers by 27 gastroenterologists were included in this study. Each individual endoscopist performed at least 10 colonoscopies during the study period. The ADR and PDR were calculated as the proportion of an endoscopist's cases with an adenoma or polyp divided by the total number of colonoscopies. Pearson's correlation coefficient and the intraclass correlation coefficient were used to determine the level of agreement between ADR and PDR. Results: The mean PDR and ADR for endoscopists was 47.4% (range, 21.7-75.0) and 36.5% (range, 13.0-66.7), respectively. There was a strong correlation between PDR and ADR (Pearson's correlation coefficient 0.94, P<0.001) and there was also good agreement between performance quintiles defined by ADR and PDR (intraclass correlation coefficient 0.94, P<0.001). Conclusions: PDR is a valid proxy for ADR and may be useful for quality assurance at centers where ADR cannot be easily measured. (Intest Res 2011;9:105-111)

Citations

Citations to this article as recorded by  
  • Usefulness of Polyp and Adenoma Detection Rate in the Proximal and Distal Colon
    Sung Youn Choi, Dong Il Park, Chang Kyun Lee, Jae Myung Cha, Suck Ho Lee, Young Whangbo, Chang Soo Eun, Dong Soo Han, Bo In Lee, Jeong Eun Shin
    The Korean Journal of Gastroenterology.2014; 63(1): 11.     CrossRef
  • Correlation between Adenoma Detection Rate and Advanced Adenoma Detection Rate
    Shin Yeoung Lee, Nam Hee Kim, Hyun Beom Chae, Ki Joong Han, Tae Hoon Lee, Choel Min Jang, Kyung Mo Yoo, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Dong Il Park
    The Korean Journal of Gastroenterology.2014; 64(1): 18.     CrossRef
  • The Correlation between Polyp Detection Rate and Adenoma Detection Rate: Mainly Determined by the Colon Segment
    Geom Seog Seo
    The Korean Journal of Gastroenterology.2014; 63(1): 1.     CrossRef
  • 2,988 View
  • 26 Download
  • 3 Crossref
Close layer
Case Report
A Case of Degos' Disease Presenting with Abdominal Angina and Widespread Skin Lesions
Bon-Ho Ku, Yeun Jung Lim, Hyo Kyung Choi, Young Ho Kim, Jongwook Park, Chi Hoon Kim, Tae-Hoon Jang, Yong Woo Seo, Young Cheol Jo, Kee-Taek Jang, Chang Ohk Sung, Dong-Kyung Chang
Intest Res 2010;8(1):70-74.   Published online June 30, 2010
DOI: https://doi.org/10.5217/ir.2010.8.1.70
AbstractAbstract PDF
Malignant atrophic papulosis (MAP), also known as Degos' disease, is a rare and often fatal occlusive thrombotic vasculopathy, with fewer than seven cases reported in Korea. MAP is characterized by porcelain-white, atrophic, papular skin lesions and multi-organ system involvement, especially the gastrointestinal (GI) tract and nervous system. Involvement of the GI tract is usually associated with a poor prognosis. To date, no treatment has been shown to be effective in the treatment of MAP. We describe a 52-year-old man who presented with a 5-month history of abdominal angina and a 2-year history of multiple skin lesions on the trunk and extremities. The skin lesions were papules, 4-6 mm in diameter, with a porcelain-white center and a slightly raised erythematous telangiectatic rim. A biopsy of a skin lesion showed a wedge-shaped degeneration of collagen in the dermis and atrophic epidermis. An explorative laparoscopy revealed multiple, yellow-white plaques scattered throughout the small bowel. A biopsy of the small bowel showed sclerotic vascular alterations containing intravascular fibrin thrombi. He was started on aspirin (100 mg daily) and has survived for 24 months since the onset of gastrointestinal symptoms. (Intest Res 2010;8:70-74)
  • 2,349 View
  • 14 Download
Close layer
Original Article
The Effectiveness of Audiovisual Aids Education in Preparing Patients for Colonoscopy
Byung Hoon Min, Dong Kyung Chang, Young Ho Kim, Poong-Lyul Rhee, Jae J. Kim, Jong Chul Rhee
Published online June 30, 2007  
AbstractAbstract PDF
Background/Aims
The purpose of this study is to investigate how effectively audiovisual aids education can improve patients' bowel preparation and their satisfaction during colonoscopic examination. Methods: The control group consisted of 116 patients and the experimental group consisted of 109 patients. The control group was given the existing test guidebooks and the experimental group was offered audiovisual aids education immediately before the test. After the test, the patients assessed. Results: In regard to the organization and consistency of colonoscopic education, the experimental group showed a statistically significant score (p=0.000). In regard to satisfaction with the colonoscopy, the average score of the control group was 7.50⁑2.02, while that of the experimental group was 8.63⁑1.76 (p=0.000). In regard to bowel preparation, the experimental group showed a statistically meaningful score compared to that of the control group (p=0.002). In terms of examination time comparison, the experimental group returned a statistically meaningful score (p=0.005). In regard to the nurses' task satisfaction, according to the information offered, the experimental group showed a statistically significant score (8.47⁑1.32) compared to the control group (6.49⁑2.23)(p=0.000). Conclusions: The audiovisual aids education enhanced the patients' satisfaction. Therefore these aids are worth incorporating within nursing methods. (Intest Res 2007;5:52-59)
  • 1,524 View
  • 32 Download
Close layer
Case Report
A Case of C1 Esterase Inhibitor Deficiency Presenting as Recurrent Abdominal Pain and Ascites
Byung Hoon Min, Dong Kyung Chang, Young Ho Kim, Poong-Lyul Rhee, Jae J. Kim, Jong Chul Rhee
Published online June 30, 2007  
AbstractAbstract PDF
C1 esterase inhibitor deficiency is a disorder resulting from a qualitative or functional defect of the C1 esterase inhibitor. It is characterized by recurrent episodes of subcutaneous and submucosal swellings in any part of the skin and the respiratory and gastrointestinal tracts. Gastrointestinal symptoms such as abdominal pain are the dominant symptoms in about 25% of cases and sometimes make this condition misunderstood as surgical emergency, especially when ascites is accompanied. We experienced a case of C1 esterase inhibitor deficiency in a 35-year-old woman presenting with recurrent abdominal pain, ascites, and lower extremities edema. Her symptoms first occurred 8 years ago, and used to spontaneously resolve within 3 days. In laboratory finding, serum C4 and serum C1 esterase inhibitor showed reduced level of 3.2 mg/dL and 5 mg/dL, respectively. After treatment with danazol and tranexamic acid, no more recurrence of symptoms was observed during 2 months of follow-up period. (Intest Res 2007;5:73-76)
  • 1,565 View
  • 19 Download
Close layer
Original Article
Acute Diarrhea after Bone Marrow Transplantation
Hyun Joo Suh, Young Ho Kim, Ji Hyang Kim, Yong Sung Choi, Jeong Kim, Poong Lyul Rhee, Jae J. Kim, Seung Woon Paik, Jong Chul Rhee
Intest Res 2005;3(2):104-109.   Published online December 30, 2005
AbstractAbstract PDF
Background/Aims
A few study have performed the cause of acute diarrhea in patients undergoing bone marrow transplantation (BMT) so far. We analyzed the prevalence of acute diarrhea after BMT, its etiology and its risk factors. Methods: We retrospectively evaluated records of 132 patients undergoing BMT between September 1999 and Jun 2003. Diarrhea had to get its onset from day of admission to day of 100 posttransplant. Results: 95 patients developed acute diarrhea in 132 patients (72% of incidence). The total episodes of diarrhea were 117. Infection was found in 16 of 117 episodes (13.7%). Acute Graft versus host disease was responsible for 9 of 117 episodes (10.3%). Possible etiology of diarrhea was composed of 19 episodes of medication-induced diarrhea (16.2%), 11 episodes of mucositis (9.4%) and 5 episodes of infection (4.3%). Unknown originated diarrhea were 56 episodes (47.9%). Development of diarrhea was not significantly associated with age, sex, underlying disease, BMT conditions and prophylaxis of CMV virus. Conclusions: Acute diarrhea was common in patients undergoing BMT. However, etiology have not clearly evaluated in half of the cases. Further tests to evaluate etiology of acute diarrhea should be investigated. (Intest Res 2005;3:104-109)
  • 1,738 View
  • 23 Download
Close layer
Case Report
A Case of Mesenteric Vasculitis Induced by Norpal Cactus Extract
Jung Su Ha, Dong Kyung Chang, Jun Haeng Lee, Young Ho Kim, Hee Jung Son, Poong Lyul Rhee, Jae J. Kim, Seung Woon Paik, Jong Chul Rhee
Intest Res 2005;3(1):85-88.   Published online June 30, 2005
AbstractAbstract PDF
Herbs are inadvertently regarded safe and harmless because of their natural origin and the experience of long-term use as a folk medicine. However, some herbal medicines are associated with toxicities in the organs such as liver, kidney, skin, or heart. Norpal cactus extract is a kind of herbs which is used for ordinary food in Mexico, and has effects on hypergylcemia and hypercholesterolemia, and inflammation. There has been no particular reports of drug-induced vasculitis by herbal medicine. Here, we present a case of vasculitis that was initially manifestated as acute diarrhea and abdominal pain after ingestion of Norpal cactus extract. (Intest Res 2005;3:85-89)
  • 1,458 View
  • 15 Download
Close layer

Intest Res : Intestinal Research
Close layer
TOP